Evidence map›Paper›PMID 42888490›Full record

ArticleJournal of diabetes2026

Urinary Liver-Type Fatty Acid-Binding Protein, Albuminuria, and eGFR Trajectories in Type 2 Diabetes.

Hiroaki Satoh, Shotaro Nakamura, Ayako Haba, Naoki Sekine, Daisuke Sugimoto

Abstract read
In one paragraph

Article in Journal of diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hiroaki SatohDepartment of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.ORCID https://orcid.org/0000-0002-0353-5807
Shotaro NakamuraDepartment of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.ORCID https://orcid.org/0009-0007-4179-0175
Ayako HabaDepartment of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.
Naoki SekineDepartment of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.
Daisuke SugimotoDepartment of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.ORCID https://orcid.org/0000-0003-0943-0712

Funding

JSPS KAKENHI JP23K10969
6 · The paper itself

Abstract

backgroundUrinary liver-type fatty acid-binding protein (L-FABP) reflects proximal tubular stress and has been proposed as a biomarker of diabetic kidney disease. We examined whether urinary L-FABP provides information on longitudinal kidney function beyond urinary albumin-to-creatinine ratio (UACR).

methodsThis retrospective cohort study included patients with type 2 diabetes who had UACR and urinary L-FABP measured simultaneously at the initial visit and underwent outpatient follow-up. The analysis included patients with at least three eGFR measurements over at least 2 years. eGFR trajectories were evaluated using linear mixed-effects models with random intercepts and slopes. UACR and L-FABP were analyzed as log(1 + x)-transformed continuous variables.

resultsThe analysis included 1,031 patients (age 58.1 years; 65.1% men), with a median follow-up of 4.76 years and a median of 10 eGFR measurements. Urinary L-FABP correlated with UACR (Spearman ρ = 0.526; p < 0.001). Both biomarkers were independently associated with lower baseline eGFR. In a model without UACR, higher L-FABP was associated with faster eGFR decline (-0.98 mL/min/1.73 m²/year per unit increase in log[1 + L-FABP]; p < 0.001). After adjustment for continuous UACR, the association was attenuated and no longer significant (-0.19; 95% CI, -0.49 to 0.11; p = 0.221), whereas UACR remained independently associated with eGFR decline. Results were unchanged after further adjustment for baseline eGFR and lipid parameters.

conclusionsUrinary L-FABP was associated with baseline kidney impairment but did not independently predict eGFR trajectory after continuous UACR was taken into account. Urinary L-FABP reflects kidney injury severity, although its incremental prognostic value beyond quantitatively assessed albuminuria was limited in this cohort.

Indexed as

AlbuminuriaDiabetes Mellitus, Type 2Diabetic NephropathiesFatty Acid-Binding ProteinsGlomerular Filtration RateAgedBiomarkersCreatinineFemaleHumansMaleMiddle AgedRetrospective StudiesBiomarkersCreatinineFABP1 protein, humanFatty Acid-Binding Proteinsalbuminuriadiabetic kidney diseaseeGFR trajectoryType 2 diabetesurinary liver‐type fatty acid‐binding protein

Identifiers

PMID42888490
PMCPMC13675519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.